Form 8-K IONIS PHARMACEUTICALS For: May 03
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Citi Upgrades Ionis Pharmaceuticals (IONS) to Neutral
May 4, 2023 6:27 AM EDTCiti analyst David Lebowitz upgraded Ionis Pharmaceuticals (NASDAQ: IONS) from Sell to Neutral with a price target of $36.00 (from $30.00).
The analyst comments "Upgrading to Neutral, Raising PT to $36 (+$6) Eplontersen prospects in ATTR is a key driver for LT growth. Recently reported full data continues to suggest eplontersen is... More
